Exelixis v. Intas (1:26-cv-00814): Litigation Summary, Patent Claims, and Potential Generic Entry Impact
Executive summary
Case: Exelixis, Inc. v. Intas Pharmaceuticals Ltd.
Court/docket: U.S. District Court, 1:26-cv-00814
Core issue: Patent infringement and related relief tied to an Exelixis product and/or its Orange Book-listed patents, asserted against Intas in the context of generic or alternative entry under Hatch-Waxman.
Business impact to watch: Whether the asserted patents include composition, formulation, method-of-use, or manufacturing claims, and whether Intas’s application is likely positioned for a Paragraph IV attack or a carve-out/section 505(b)(2) pathway. The scope and claim selection drive both design-around feasibility and the timing risk for generic launch.
No litigation filings, claim charts, complaint text, or patent list were provided in the prompt. Without the underlying docket contents (complaint, answers, motions, and PTAB/Fed. Cir. activity if any), a complete and accurate litigation summary cannot be produced.
What patents are at issue in Exelixis v. Intas 1:26-cv-00814?
Answer (required for an infringement and exclusivity-risk…
